ZA978557B - Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease. - Google Patents

Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease.

Info

Publication number
ZA978557B
ZA978557B ZA9708557A ZA978557A ZA978557B ZA 978557 B ZA978557 B ZA 978557B ZA 9708557 A ZA9708557 A ZA 9708557A ZA 978557 A ZA978557 A ZA 978557A ZA 978557 B ZA978557 B ZA 978557B
Authority
ZA
South Africa
Prior art keywords
alzheimer
disease
agents
determination
treatment
Prior art date
Application number
ZA9708557A
Inventor
Thomas Dyrks
Jonathan-David Turner
Marion Haertel
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ZA978557B publication Critical patent/ZA978557B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA9708557A 1996-09-24 1997-09-23 Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease. ZA978557B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19641180A DE19641180A1 (en) 1996-09-24 1996-09-24 A method of displaying APP secretase modulation and its use as an agent for the treatment of Alzheimer's disease

Publications (1)

Publication Number Publication Date
ZA978557B true ZA978557B (en) 1998-03-26

Family

ID=7807996

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9708557A ZA978557B (en) 1996-09-24 1997-09-23 Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease.

Country Status (4)

Country Link
AU (1) AU4775797A (en)
DE (1) DE19641180A1 (en)
WO (1) WO1998013488A2 (en)
ZA (1) ZA978557B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679534B2 (en) 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
SG113454A1 (en) 1998-09-24 2005-08-29 Upjohn Co Alzheimer's disease secretase
US6699671B1 (en) 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6844148B1 (en) 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6313268B1 (en) 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
US6245884B1 (en) 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US7115410B1 (en) 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
CA2359785A1 (en) 1999-02-10 2000-08-17 John P. Anderson .beta.-secretase enzyme compositions and methods
DE19920514A1 (en) * 1999-05-05 2000-11-16 Boehringer Ingelheim Pharma Methods for finding proteases that specifically cleave membrane-bound substrates
US6545127B1 (en) 1999-06-28 2003-04-08 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
DE19941039A1 (en) * 1999-08-28 2001-03-01 Boehringer Ingelheim Pharma gamma-secretase in vitro test system
US7514408B1 (en) 1999-12-02 2009-04-07 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
WO2001058476A2 (en) * 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
CA2401155A1 (en) * 2000-04-05 2001-10-11 Alcide Barberis Method for identify polypeptides with protease activity
CA2313828A1 (en) * 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
CA2437480A1 (en) * 2001-02-05 2002-08-15 Andrx Corporation Method of treating amyloid .beta. precursor disorder
AU2002359301B2 (en) 2001-10-23 2008-07-03 Comentis, Inc. Beta-secretase inhibitors and methods of use
US7045311B2 (en) 2001-10-25 2006-05-16 Monogram Biosciences, Inc. Whole cell assay systems for cell surface proteases
CH698246B1 (en) * 2001-12-20 2009-06-30 Hoffmann La Roche Test to identify inhibitors of beta secretases.
WO2003087842A1 (en) * 2002-04-18 2003-10-23 Esbatech Ag Method for the identification of modulators of a secretase activity
JP2004000060A (en) * 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd METHOD FOR SCREENING COMPOUND AFFECTING PRODUCTION OF AMYLOID beta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327960A1 (en) * 1988-02-11 1989-08-16 F. Hoffmann-La Roche Ag Secretable forms of alkaline phosphatase
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
AU679675B2 (en) * 1992-05-11 1997-07-10 Bayer Corporation Methods for detecting beta amyloid precursor protein processing enzymes
ZA936492B (en) * 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
DE69334337D1 (en) * 1992-10-26 2010-08-26 Elan Pharm Inc Method for identifying inhibitor compounds of the release of beta-amyloid peptide (BAP)
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AU6383396A (en) * 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition

Also Published As

Publication number Publication date
DE19641180A1 (en) 1998-03-26
WO1998013488A2 (en) 1998-04-02
WO1998013488A3 (en) 1998-09-11
AU4775797A (en) 1998-04-17

Similar Documents

Publication Publication Date Title
ZA978557B (en) Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease.
EP1007048A4 (en) Identification of agents for use in the treatment of alzheimer's disease
EP1043991A4 (en) Treatment for alzheimer's disease
GB2367060B (en) Alzheimer's disease secretase,app substrates therefor,and uses therefor
EP0963219A4 (en) Manipulations of nitrosative and oxidatives stress in the treatment of disease
PL348226A1 (en) Compounds for the antemortem diagnosis of alzheimer's disease and in vivo
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
AU5716898A (en) Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
IL105216A0 (en) Method and kit for the diagnosis of alzheimer's disease
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
AU3279395A (en) Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
EP0685219A3 (en) Hair treatment agent and process for its use.
EP0691112A3 (en) Ophthalmic treatment apparatus and its use
EP1011644A4 (en) Methods and apparatus for treatment of parkinson's disease
IL127146A0 (en) Transdermal propentofylline compositions for the treatment of alzheimer's disease
ZA989365B (en) Preparation for treating alzheimer's disease
ZA964761B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
AU3745895A (en) Use of gaba antagonists in the treatment of emesis
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
AU1405899A (en) Treatment for alzheimer's disease
AU2002301084A1 (en) Identification of agents for use in the treatment of alzheimer's disease
ZA947262B (en) Use of transdermal device containing (e)-2-(p-fluorophenethyl)-3-fluoroallylamine and its use for the treatment of alzheimer's disease
ZA9610264B (en) Preparation for use in the treatment of skin disorders.
GB2357767B (en) Alzheimer's disease secretase app substrates therefor and uses therefor
GB9709416D0 (en) Methods for treatment of alzheimer's disease using azaspiranes